Temporal trends, safety, and efficacy of bivalirudin in elective percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium

Journal of Interventional Cardiology

Volumn 20, Issue 3, 2007, Pages 197-203

  Gurm, Hitinder S ^a   Smith, Dean E ^a   Chetcuti, Stan J ^a   Share, David ^b   Khanal, Sanjaya ^c   Riba, Arthur ^d   Carter, Andrew J ^e   Lalonde, Thomas ^f   Kline Rogers, Eva ^a   O'Donnell, Michael ^g   O'Neill, William ^h   Safian, Robert ^h   Moscucci, Mauro ^b,i  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Blue Cross Blue Shield of Michigan Cardiovascular Consortium   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d Oakwood Healthcare Inc   (United States)

^e BORGESS MEDICAL CENTER   (United States)

^f ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^g ST JOSEPH MERCY HOSPITAL   (United States)

^h WILLIAM BEAUMONT HOSPITAL   (United States)

ⁱ UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIURETIC AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; TIROFIBAN; WARFARIN;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STROKE; TREATMENT OUTCOME; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CORONARY ARTERIOSCLEROSIS; FEMALE; HEPARIN; HIRUDINS; HUMANS; MALE; MICHIGAN; MIDDLE AGED; PEPTIDE FRAGMENTS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS; REGISTRIES; RISK FACTORS; SURGICAL PROCEDURES, ELECTIVE; TIME FACTORS; TREATMENT OUTCOME;

EID: 34249668866     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2007.00262.x     Document Type: Article

References (21)

1. EPISTENT investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998 352 : 87 92.
2. EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994 330 : 956 961.
3. EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997 336 : 1689 1696.
4. Topol EJ, Lincoff AM, Kereiakes DJ, et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med. 2002 113 : 1 6.
5. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003 289 : 853 863.
6. Kline-Rogers E, Share D, Bondie D, et al. Development of a multicenter interventional cardiology database: The Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) experience. J Interv Cardiol 2002 15 : 387 392.
7. Moscucci M, Kline-Rogers E, Share D, et al. Simple bedside additive tool for prediction of in-hospital mortality after percutaneous coronary interventions. Circulation 2001 104 : 263 268.
8. Moscucci M, Eagle KA, Share D, et al. Public reporting and case selection for percutaneous coronary interventions: An analysis from two large multicenter percutaneous coronary intervention databases. J Am Coll Cardiol 2005 45 : 1759 1765.
9. Moscucci M, Rogers EK, Montoye C, et al. Association of a continuous quality improvement initiative with practice and outcome variations of contemporary percutaneous coronary interventions. Circulation 2006 113 : 814 822.
10. Moscucci M, O'Connor GT, Ellis SG, et al. Validation of risk adjustment models for in-hospital percutaneous transluminal coronary angioplasty mortality on an independent data set. J Am Coll Cardiol 1999 34 : 692 697.
11. D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998 17 : 2265 2281.
12. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999 353 : 227 231.
13. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomized, placebo-controlled trial. Lancet 2000 356 : 2037 2044.
14. Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003 41 : 26 32.
15. Horwitz PA, Berlin JA, Sauer WH, et al. Bleeding risk of platelet glycoprotein IIb/IIIa receptor antagonists in broad-based practice (results from the Society for Cardiac Angiography and Interventions Registry). Am J Cardiol 2003 91 : 803 806.
16. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001 142 : 952 959.
17. Gurm HS, Rajagopal V, Fathi R, et al. Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center. Am J Cardiol 2005 95 : 716 721.
18. Eitzman DT, Chi L, Saggin L, et al. Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4. Circulation 1994 89 : 1523 1529.
19. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998 97 : 251 256.
20. Hirsh J. Heparin. N Engl J Med 1991 324 : 1565 1574.
21. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990 86 : 385 391.